| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (NCT04006522) | James Brugarolas | 2019-10-02 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy (NCT04623502) | University of Texas Southwestern Medical Center | 2019-09-30 |
| Prospective Trial for Examining Hematuria Using Computed Tomography (NCT04077359) | Oslo University Hospital | 2019-09-15 |
| LPN in Patients With High-complex Renal Tumors (NCT04933604) | Samsun Liv Hospital | 2019-09-01 |
| Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer (NCT04022343) | Emory University | 2019-08-06 |
| A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal (NCT05168436) | Bristol-Myers Squibb | 2019-08-05 |
| Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy (NCT04309617) | Pfizer | 2019-07-31 |
| Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (NCT03937219) | Exelixis | 2019-06-25 |
| A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (NCT03873402) | Bristol-Myers Squibb | 2019-06-21 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| Biomarkers of Renal Cancer (NCT05785052) | Biorek S.R.L. | 2019-06-11 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (NCT03786796) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-06-03 |
| Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma (NCT03987698) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (NCT03798626) | Novartis Pharmaceuticals | 2019-05-22 |
| Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients (NCT03776123) | Ipsen | 2019-05-15 |
| Renal Cell Carcinoma Microenvironment Discovery Project (NCT04005183) | University Health Network, Toronto | 2019-05-06 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (NCT03685448) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2019-04-11 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166) | Exelixis | 2019-03-20 |
| Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (NCT03324373) | Yousef Zakharia | 2019-03-20 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| Laparoscopic Partial Nephrectomy for cT1 Tumors (NCT04213157) | Samsun Liv Hospital | 2019-03-15 |
| Non-Invasive Diagnostics of Small Renal Masses (NCT03667885) | Odense University Hospital | 2019-03-01 |
| Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma (NCT04416646) | Istituto Oncologico Veneto IRCCS | 2019-02-27 |
| Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC (NCT03699579) | Ipsen | 2019-02-22 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors (NCT03827837) | Jiangsu HengRui Medicine Co., Ltd. | 2019-01-23 |
| A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma (NCT03693573) | Hoffmann-La Roche | 2019-01-11 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors (NCT03637803) | 4D pharma plc | 2019-01-10 |
| Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors (NCT04268368) | Università Politecnica delle Marche | 2019-01-01 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) (NCT03729245) | Nektar Therapeutics | 2018-12-18 |
| PD-L1 Expression in Japanese Renal Cell Carcinoma Patients (NCT03748901) | Chugai Pharmaceutical | 2018-12-16 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies (NCT03387514) | University of Wisconsin, Madison | 2018-12-08 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts. (NCT03744585) | Ipsen | 2018-11-06 |
| Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma (NCT03692533) | Assiut University | 2018-10-01 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) (NCT03634540) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-09-27 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread (NCT03663946) | Bristol-Myers Squibb | 2018-09-18 |
| APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC (NCT03655613) | Apollomics (Australia) Pty. Ltd. | 2018-09-05 |
| Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (NCT03323710) | Military Institute od Medicine National Research Institute | 2018-09-01 |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110) | Genocea Biosciences, Inc. | 2018-08-29 |
| A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) (NCT03207347) | University of Florida | 2018-08-13 |
| TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative (NCT03630536) | Children's Hospital Medical Center, Cincinnati | 2018-08-12 |
| Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma (NCT03552380) | Roberto Pili | 2018-07-31 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| Renal Adjuvant MultiPle Arm Randomised Trial (NCT03288532) | University College, London | 2018-07-19 |
| A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) (NCT03592472) | Xynomic Pharmaceuticals, Inc. | 2018-07-17 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) (NCT03200587) | University of Utah | 2018-06-21 |
| A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma (NCT03294083) | SillaJen, Inc. | 2018-06-19 |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330) | Yale University | 2018-06-09 |
| European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study) (NCT06336187) | Azienda Ospedaliero Universitaria Maggiore della Carita | 2018-06-01 |
| High Dose IL 2 and Entinostat in RCC (NCT03501381) | Roberto Pili | 2018-05-24 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma (NCT03541902) | M.D. Anderson Cancer Center | 2018-05-15 |
| GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors (NCT03576131) | Genmab | 2018-04-30 |
| Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma (NCT03419572) | Ipsen | 2018-04-24 |
| Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC (NCT03341845) | The Netherlands Cancer Institute | 2018-03-28 |
| Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (NCT03393936) | Shanghai PerHum Therapeutics Co., Ltd. | 2018-03-26 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (NCT03435640) | Nektar Therapeutics | 2018-03-15 |
| CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (NCT03511391) | University Hospital, Ghent | 2018-03-09 |
| RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC (NCT03259477) | Xuanwu Hospital, Beijing | 2018-02-01 |
| Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer (NCT03455452) | Bristol-Myers Squibb | 2018-01-21 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| MEtatastic Renal Carcinoma LINes (NCT03928964) | Centre Hospitalier Universitaire de Besancon | 2018-01-15 |
| CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma (NCT03427476) | Cancer Targeted Technology | 2018-01-01 |
| Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion (NCT03494816) | Scottish Clinical Trials Research Unit | 2017-12-15 |
| Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (NCT03297593) | Swiss Cancer Institute | 2017-12-13 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT (NCT01762592) | Heidelberg Pharma AG | 2017-12-01 |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma (NCT03291028) | Fox Chase Cancer Center | 2017-11-27 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (NCT03343613) | Eli Lilly and Company | 2017-11-17 |
| A Study of BCD-135 in Patients With Advanced Solid Tumors (NCT03464032) | Biocad | 2017-10-31 |
| Using Virtual Reality (VR) Models for Preoperative Planning (NCT03334344) | Ceevra, Inc. | 2017-10-24 |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (NCT03177239) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-10-19 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174) | Sarcoma Oncology Research Center, LLC | 2017-08-24 |
| Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (NCT03173560) | Eisai Inc. | 2017-08-17 |
| A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (NCT03141177) | Bristol-Myers Squibb | 2017-07-23 |
| Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas (NCT03189186) | University of California, Irvine | 2017-07-01 |
| Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma (NCT03172754) | Fox Chase Cancer Center | 2017-06-12 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) (NCT03142334) | Merck Sharp & Dohme LLC | 2017-06-09 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
| Everolimus TDM to Predict Long Term Toxicity (NCT03033186) | Maastricht University Medical Center | 2017-05-16 |
| Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) (NCT03063762) | Hoffmann-La Roche | 2017-03-20 |
| Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer (NCT02989714) | University of Michigan Rogel Cancer Center | 2017-03-16 |
| Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor (NCT03093688) | Shanghai Public Health Clinical Center | 2017-03-01 |
| Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents (NCT02928263) | Bristol-Myers Squibb | 2017-02-28 |
| Study of DC-CTL Combined With CIK for Advanced Solid Tumor (NCT03047525) | Xiaoyi Huang | 2017-02-20 |